09:57 AM EDT, 05/09/2025 (MT Newswires) -- LENZ Therapeutics ( LENZ ) has granted Lotus Pharmaceutical exclusive rights to develop and sell its potential presbyopia treatment LNZ100 in South Korea and parts of Southeast Asia, the companies said Friday.

Under the agreement, LENZ will receive up to $125 million in upfront, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on future net sales, the companies said.

The deal gives Lotus exclusive rights for development, manufacturing and sales in South Korea, and certain Southeast Asian countries including Thailand, the Philippines, Vietnam, Malaysia, Brunei, Indonesia and Singapore, the companies said.

The US Food and Drug Administration is reviewing LNZ100, and a decision is expected by Aug. 8, according to the combined statement.

LENZ shares were 1.4% higher in recent trading.

Price: 26.01, Change: +0.14, Percent Change: +0.54